InsiderClue
Stocks · Health care · In Vitro & In Vivo Diagnostic Substances

Celldex Therapeutics, Inc.

CLDX Clue Score15
United States Fiscal year ends December CIK 0000744218 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

65
Insider
Date
Role
Action
Shares
Price
Amount
Samuel Bates Martin
2 Jan 2026
SVP and CFO
Exercised, kept
4,817
$10.38
$50.00K
Ronald Pepin
15 Dec 2025
Sr. VP & Cbo
Exercised, kept
11,000
$2.78
$30.58K
Ronald Pepin
15 Dec 2025
Sr. VP & Cbo
Exercised, kept
8,333
$9.02
$75.13K
Freddy A. Jimenez
4 Dec 2025
SVP & General Counsel
Sell
4,166
$29.10
$121.21K
Richard M. Wright
13 Nov 2025
Former Officer
Sold after exercise
49,298
$24.00
$1.18M
Freddy A. Jimenez
13 Aug 2025
SVP & General Counsel
Sell
430
$25.42
$10.93K
Freddy A. Jimenez
13 Aug 2025
SVP & General Counsel
Sell
341
$23.95
$8.17K
Anthony S Marucci
11 Nov 2024
President & CEO
Buy
11,500
$26.82
$308.43K
Samuel Bates Martin
14 Jun 2024
SVP and CFO
Sold after exercise
17,172
$35.42
$608.31K
Elizabeth Crowley
14 Jun 2024
Sr. VP & Cpdo
Sold after exercise
30,000
$34.87
$1.05M
Diane C. Young
11 Jun 2024
SVP, Chief Medical Officer
Exercised, kept
15,000
$2.71
$40.65K
Diane C. Young
7 Jun 2024
SVP, Chief Medical Officer
Sell
45,000
$35.26
$1.59M
Elizabeth Crowley
7 Jun 2024
Sr. VP & Cpdo
Sold after exercise
15,000
$35.06
$525.87K
Freddy A. Jimenez
5 Jun 2024
SVP & General Counsel
Exercised, kept
9,540
$10.38
$99.03K
Freddy A. Jimenez
3 Jun 2024
SVP & General Counsel
Sold after exercise
8,006
$33.60
$269.00K
Richard M. Wright
3 Jun 2024
Sr. VP & CCO
Sold after exercise
19,264
$33.99
$654.69K
Richard M. Wright
3 Jun 2024
Sr. VP & CCO
Sold after exercise
27,580
$33.53
$924.66K
Margo Heath-Chiozzi
3 Jun 2024
SVP of Regulatory Affairs
Sold after exercise
58,369
$33.65
$1.96M
Elizabeth Crowley
30 May 2024
Sr. VP & Cpdo
Sold after exercise
38,597
$33.64
$1.30M
Sarah Cavanaugh
30 May 2024
SVP of Corp Affairs & Admin.
Sold after exercise
20,853
$33.73
$703.33K
Samuel Bates Martin
30 May 2024
SVP and CFO
Sold after exercise
35,000
$34.05
$1.19M
Margo Heath-Chiozzi
30 May 2024
SVP of Regulatory Affairs
Sold after exercise
38,719
$34.07
$1.32M
Freddy A. Jimenez
13 Feb 2024
SVP & General Counsel
Exercised, kept
20,000
$2.78
$55.60K
Freddy A. Jimenez
13 Feb 2024
SVP & General Counsel
Exercised, kept
4,166
$9.02
$37.56K
Samuel Bates Martin
2 Jan 2024
SVP and CFO
Exercised, kept
10,750
$2.78
$29.89K
Tibor Keler
7 Dec 2022
Executive VP & CSO
Sold after exercise
16,860
$36.93
$622.61K
Sarah Cavanaugh
18 Aug 2022
SVP of Corp Affairs & Admin.
Sold after exercise
1,355
$36.38
$49.29K
Diane C. Young
17 Aug 2022
SVP, Chief Medical Officer
Sold after exercise
19,000
$37.30
$708.72K
Sarah Cavanaugh
17 Aug 2022
SVP of Corp Affairs & Admin.
Sold after exercise
31,312
$36.73
$1.15M
Richard M. Wright
15 Aug 2022
Sr. VP & CCO
Sold after exercise
15,328
$37.71
$578.05K
Anthony S Marucci
15 Aug 2022
President & CEO
Sold after exercise
120,000
$37.66
$4.52M
Samuel Bates Martin
12 Aug 2022
SVP and CFO
Sold after exercise
1,221
$34.62
$42.27K
Samuel Bates Martin
12 Aug 2022
SVP and CFO
Sold after exercise
2,065
$35.38
$73.05K
Samuel Bates Martin
12 Aug 2022
SVP and CFO
Sold after exercise
14,261
$36.76
$524.30K
Samuel Bates Martin
11 Aug 2022
SVP and CFO
Sold after exercise
2,453
$37.04
$90.86K
Samuel Bates Martin
23 Dec 2021
SVP and CFO
Sold after exercise
9,500
$42.00
$399.00K
Margo Heath-Chiozzi
8 Dec 2021
SVP of Regulatory Affairs
Sold after exercise
600
$40.00
$24.00K
Elizabeth Crowley
8 Dec 2021
Sr. VP &CPDO
Sold after exercise
4,000
$40.00
$160.00K
Sarah Cavanaugh
8 Dec 2021
SVP of Corp Affairs & Admin.
Sold after exercise
7,323
$40.00
$292.92K
Samuel Bates Martin
15 Nov 2021
SVP and CFO
Sold after exercise
2,048
$42.27
$86.57K
Samuel Bates Martin
15 Nov 2021
SVP and CFO
Sold after exercise
7,452
$43.92
$327.31K
Diane C. Young
12 Nov 2021
SVP, Chief Medical Officer
Sold after exercise
4,600
$42.94
$197.53K
Margo Heath-Chiozzi
1 Nov 2021
SVP of Regulatory Affairs
Sold after exercise
600
$41.71
$25.03K
Elizabeth Crowley
1 Nov 2021
Sr. VP &CPDO
Sold after exercise
1,189
$41.62
$49.48K
Elizabeth Crowley
1 Nov 2021
Sr. VP &CPDO
Sold after exercise
600
$43.11
$25.87K
Elizabeth Crowley
1 Nov 2021
Sr. VP &CPDO
Sold after exercise
2,528
$44.12
$111.53K
Sarah Cavanaugh
1 Nov 2021
SVP of Corp Affairs & Admin.
Sold after exercise
2,120
$41.62
$88.23K
Sarah Cavanaugh
1 Nov 2021
SVP of Corp Affairs & Admin.
Sold after exercise
901
$43.06
$38.80K
Sarah Cavanaugh
1 Nov 2021
SVP of Corp Affairs & Admin.
Sold after exercise
4,302
$44.11
$189.77K
Freddy A. Jimenez
11 Aug 2021
SVP & General Counsel
Buy
430
$46.28
$19.90K
Margo Heath-Chiozzi
11 Aug 2021
SVP of Regulatory Affairs
Exercised, kept
10,000
$9.02
$90.17K
Samuel Bates Martin
10 Aug 2021
SVP and CFO
Sold after exercise
682
$45.25
$30.86K
Samuel Bates Martin
10 Aug 2021
SVP and CFO
Sold after exercise
2,056
$45.25
$93.03K
Anthony S Marucci
5 Aug 2021
President & CEO
Exercised, kept
3,537
$42.00
$148.55K
Richard M. Wright
14 Dec 2020
Sr. VP & CCO
Sold after exercise
9,375
$18.61
$174.44K
Richard M. Wright
14 Dec 2020
Sr. VP & CCO
Sold after exercise
11,457
$18.61
$213.17K
Diane C. Young
11 Jun 2020
SVP, Chief Medical Officer
Buy
2,115
$4.73
$10.00K
Sarah Cavanaugh
10 Jun 2020
SVP of Corp Affairs & Admin.
Buy
1,050
$4.83
$5.07K
Anthony S Marucci
9 Jun 2020
President & CEO
Buy
15,000
$3.06
$45.90K
Tibor Keler
9 Jun 2020
Executive VP & CSO
Buy
5,000
$2.99
$14.95K
James J Marino
9 Jun 2020
Director
Buy
8,305
$3.00
$24.92K
Samuel Bates Martin
9 Jun 2020
SVP and CFO
Buy
9,750
$3.05
$29.74K
Margo Heath-Chiozzi
9 Jun 2020
SVP of Regulatory Affairs
Buy
1,000
$3.01
$3.01K
James J Marino
24 Aug 2018
Director
Buy
40,000
$0.48
$19.20K
Tibor Keler
15 Jun 2018
Executive VP & CSO
Buy
16,500
$0.59
$9.78K

What was left out

Form 4 filings counted 238
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 40
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 1,008,121
History held since 8 Jan 2007